London is the UK’s largest startup hub, home to companies working across artificial intelligence, life sciences, fintech, defence and clean energy. Using Beauhurst data, we’ve ranked the top 100 London startups by the total amount of equity funding they have raised.
Across our wider cohort of 104 companies, £13.1b has been raised through 395 equity rounds. And 2026 is already a record year: these businesses secured £3.53b in the first nine months alone, more than in any previous full year.
This is not a ranking of London’s largest technology companies or highest-revenue businesses. Instead, it highlights early-stage London companies that have attracted the most equity investment—and what the data tells us about the wider London startup ecosystem.
The London startup scene
For this ranking, a startup is a company at the seed or venture stage of evolution on the Beauhurst platform. These are Beauhurst’s two earliest stages, based on trading history, funding patterns and company maturity.
That means every company included is still relatively early in its journey, even though several have already raised sums that would be substantial for a listed business.
The cohort broadly falls into three areas:
- AI and software: model developers, compute infrastructure and software built for specific industries and business functions
- Life sciences: drug developers, cell and gene therapy companies, and AI platforms used to design new medicines
- Fintech and payments: payment processing, lending, insurance and digital asset infrastructure
Application software applies to 61 of the 104 companies in our cohort. Pharmaceuticals applies to 29, biotechnology to 22 and clinical research to 20.
That life sciences weighting is notable. Almost three in ten of the startups in our analysis are developing drugs, despite London often being associated more closely with software and fintech.
There are 104 companies in the wider cohort today, compared with 56 at the end of 2020. Of these, 87 are at venture stage and 17 at seed stage.
New company formation has slowed. Sixteen companies in the cohort were founded in 2020 and 15 in 2019, compared with five in 2025 and two so far in 2026.
How much funding have London startups raised?
The companies in our analysis have raised £13.1b across 395 equity rounds.
Isomorphic Labs leads the ranking with £2.02b. The DeepMind spinout raised a $2.1b Series B in May 2026 to fund its AI drug design platform.
Autolus follows with £1.06b, ahead of Cambridge Aerospace (£445m), Ki Insurance (£385m) and Karma Kitchen (£352m).
Funding is concentrated, but not to the same extent as in some other sectors and regions. Isomorphic Labs accounts for 15% of the total, while the five highest-funded companies account for 32% and the top 10 for 42%.
The scale of recent rounds is particularly striking. Companies raised £3.53b in the first nine months of 2026—27% of all capital recorded across the cohort. Overall, 89% of the capital in this analysis has been raised since 2020.
Who invests in London startups?
London startups are backed by a mix of UK venture capital firms and international growth investors.
By number of rounds, AlbionVC is the most active investor with 16, followed by Index Ventures with 13, F-Prime Capital Partners with 12 and LocalGlobe with nine. Accel and Creandum have participated in eight rounds each.
By value, the largest figures belong to investors participating in the cohort’s biggest rounds. GV appears in rounds totalling £2.11b, followed by Alphabet and Thrive Capital at £2.02b each, and the UK Government’s Sovereign AI Fund at £1.73b.
These totals reflect participation in shared rounds rather than separate investments. The presence of the Sovereign AI Fund also shows the growing role of public capital in large private financings.
What do London startups work on?
Three areas account for much of the activity in our cohort.
AI and software has attracted the largest individual funding rounds and includes many of the newest companies. Life sciences accounts for the largest group after software, with businesses typically raising over longer periods to fund research and clinical trials. Fintech remains substantial by company count, but no longer produces the cohort’s largest fundraisings.
